Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

doi:10.1016/S1470-2045(17)30180-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

The Lancet. Oncology - 1 Apr 2017

Dummer Reinhard, Schadendorf Dirk, Ascierto Paolo A, Arance Ana, Dutriaux Caroline, Di Giacomo Anna Maria, Rutkowski Piotr, Del Vecchio Michele, Gutzmer Ralf, Mandala Mario, Thomas Luc, Demidov Lev, Garbe Claus, Hogg David, Liszkay Gabriella, Queirolo Paola, Wasserman Ernesto, Ford James, Weill Marine, Sirulnik L Andres, Jehl Valentine, Bozón Viviana, Long Georgina V, Flaherty Keith

Abstract excerpt

BACKGROUND: There are no established therapies specific for NRAS-mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melanoma. METHODS: NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Dacarbazine

Share to Follow-Up Studies

Share to GTP Phosphohydrolases

Share to Melanoma

Share to Neoplasm Staging

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 28284557
DOI: 10.1016/S1470-2045(17)30180-8

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.PMID 28284557Read ↗

Binimetinib for the treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

An overview of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

The discovery and development of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

A review of binimetinib for the treatment of mutant cutaneous melanoma.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.Semantic proximity Read ↗

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.Semantic proximity Read ↗

Treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.Semantic proximity Read ↗

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Semantic proximity Read ↗

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.Semantic proximity Read ↗

MEK inhibitors for the treatment of NRAS mutant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.